Literature DB >> 20402539

Single technology appraisal at the UK National Institute for Health and clinical excellence: a source of evidence and analysis for decision making internationally.

Mark Sculpher.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20402539     DOI： 10.2165/11535680-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  12 in total

1.  Single technology appraisals by NICE: are they delivering faster guidance to the NHS?

Authors:  Leela Barham
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

2.  Access with evidence development: the US experience.

Authors:  Penny E Mohr; Sean R Tunis
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products.

Authors:  Adrian Towse; Louis P Garrison
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Access with evidence development schemes: a framework for description and evaluation.

Authors:  Christopher J McCabe; Tania Stafinski; Richard Edlin; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

5.  Principles of design of access with evidence development approaches: a consensus statement from the Banff Summit.

Authors:  Devidas Menon; Christopher J McCabe; Tania Stafinski; Richard Edlin
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

6.  We know accurately only when we know little.

Authors:  Stuart MacLeod; Craig Mitton
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

7.  Comparing methods for full versus single technology appraisal: a case study of docetaxel and paclitaxel for early breast cancer.

Authors:  Eva Kaltenthaler; Paul Tappenden; Andrew Booth; Ron Akehurst
Journal:  Health Policy       Date:  2008-04-02       Impact factor: 2.980

Review 8.  Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal.

Authors:  Adrian Bagust; Janette Greenhalgh; Angela Boland; Nigel Fleeman; Claire McLeod; Rumona Dickson; Yenal Dundar; Christine Proudlove; Richard Shaw
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 9.  Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal.

Authors:  Mark Rodgers; Susan Griffin; Mike Paulden; Russell Slack; Steven Duffy; John R Ingram; Nerys Woolacott; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

Review 10.  Funding the unfundable: mechanisms for managing uncertainty in decisions on the introduction of new and innovative technologies into healthcare systems.

Authors:  Tania Stafinski; Christopher J McCabe; Devidas Menon
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981
View more
  22 in total

1.  Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.

Authors:  Tania Stafinski; Devidas Menon; Caroline Davis; Christopher McCabe
Journal:  Clinicoecon Outcomes Res       Date:  2011-08-30

Review 2.  Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal.

Authors:  Dwayne Boyers; Xueli Jia; David Jenkinson; Graham Mowatt
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

Review 3.  Ruxolitinib for the treatment of myelofibrosis: a NICE single technology appraisal.

Authors:  Ros Wade; Micah Rose; Aileen Rae Neilson; Lisa Stirk; Rocio Rodriguez-Lopez; David Bowen; Dawn Craig; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2013-10       Impact factor: 4.981

Review 4.  Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal.

Authors:  Huiqin Yang; Dawn Craig; David Epstein; Laura Bojke; Kate Light; Ian N Bruce; Mark Sculpher; Nerys Woolacott
Journal:  Pharmacoeconomics       Date:  2012-04       Impact factor: 4.981

Review 5.  Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal.

Authors:  E L Simpson; P Fitzgerald; P Evans; P Tappenden; N Kalita; J P D Reckless; A Bakhai
Journal:  Pharmacoeconomics       Date:  2013-04       Impact factor: 4.981

Review 6.  Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.

Authors:  Sophie Whyte; Abdullah Pandor; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2012-12-01       Impact factor: 4.981

Review 7.  Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar I disorder in children and adolescents: a NICE single technology appraisal.

Authors:  Lesley Uttley; Ben Kearns; Shijie Ren; Matt Stevenson
Journal:  Pharmacoeconomics       Date:  2013-11       Impact factor: 4.981

Review 8.  Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.

Authors:  Nigel Armstrong; Manuela Joore; Thea van Asselt; Kate Misso; Nathan Manning; Florian Tomini; Jos Kleijnen; Rob Riemsma
Journal:  Pharmacoeconomics       Date:  2013-05       Impact factor: 4.981

Review 9.  Cabazitaxel for the second-line treatment of metastatic hormone-refractory prostate cancer: a NICE single technology appraisal.

Authors:  Ben Kearns; Myfanwy Lloyd Jones; Matt Stevenson; Chris Littlewood
Journal:  Pharmacoeconomics       Date:  2013-06       Impact factor: 4.981

Review 10.  Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisal.

Authors:  Eldon Spackman; Stephen Rice; Gill Norman; Dong-Churl Suh; Alison Eastwood; Stephen Palmer
Journal:  Pharmacoeconomics       Date:  2013-03       Impact factor: 4.981
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.